Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

QUETIAPINE

All products: general benefit

Other products in the same Health Canada class (N05A, N05AH) — coverage varies; not interchangeable

  • Asenapine (Saphris): general benefit
  • Loxapine (Loxapac): general benefit, Not a benefit
  • Olanzapine (Zyprexa Zydis): general benefit, Not a benefit
  • Clozapine (AA-Clozapine Tablet): not a benefit
  • Aripiprazole (Abilify Asimtufii): general benefit
  • Brexpiprazole (Rexulti): general benefit

18 more in the class list below

Seroquel · DIN 02236953 · 200mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists SEROQUEL (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Seroquel · DIN 02236953 Manufacturer: AstraZeneca; listing date 1998-12-31 Health Canada: Marketed since 2025-10-24 · brand SEROQUEL · ATC N05AH04 QUETIAPINE · form Tablet · route Oral · ingredients QUETIAPINE (QUETIAPINE FUMARATE) 200 MG · company Cheplapharm arzneimittel gmbh · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2647 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60247 · Verify on the e-Formulary ↗ (DIN 02236953)

Source record
DIN 02236953: Seroquel Raw flags: sec3=Y Item: 281608193; group id 506; item number 1324; lccId None; manufacturer id AZC Source form: Tab; strength: 200mg Recorded listing: General benefit Source prices (unrounded): $2.9416; ministry $0.2647 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02236953 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60247
Interchangeable products
Act Quetiapine · DIN 02316110 · $0.2647 Apo-Quetiapine · DIN 02313936 · $0.2647 Apo-Quetiapine Fumarate · DIN 02501651 · $0.2647 Auro-Quetiapine · DIN 02390248 · $0.2647 Bio-Quetiapine · DIN 02447223 · $0.2647 Jamp Quetiapine Fumarate · DIN 02390167 · $0.2647 Jamp-Quetiapine · DIN 02330458 · $0.2647 Mar-Quetiapine · DIN 02399849 · $0.2647 Mint-Quetiapine · DIN 02438046 · $0.2647 PMS-Quetiapine · DIN 02296594 · $0.2647 Quetiapine · DIN 02317923 · $0.2647 Quetiapine · DIN 02353199 · $0.2647 Quetiapine Tablets · DIN 02387824 · $0.2647 Ran-Quetiapine · DIN 02397110 · $0.2647 Sandoz Quetiapine · DIN 02314010 · $0.2647 Teva-Quetiapine · DIN 02284278 · $0.2647
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02236953
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

LOXAPINE SUCCINATE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab

OLANZAPINE

· 116 products · General benefit (99), Off-Formulary Interchangeable, not an ODB benefit (17) · strengths: 5mg, 10mg, 15mg, 20mg, 2.5mg, 7.5mg · Rapid Dissolve Tab, Tab

CLOZAPINE

· 14 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg, 200mg, 25mg, 100mg ·

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

FLUPHENAZINE HCL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 1mg, 2mg, 5mg · Tab

HALOPERIDOL

· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: the manifestations of schizophrenia
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE LURASIDONE HYDROCHLORIDE · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4), General benefit (33), Listed, not a benefit (1) INDICATIONS AND CLINICAL USE Adults Schizophrenia Taro-Lurasidone (lurasidone hydrochloride tablets) is indicated for the management of the manifestations of schizophrenia. PM: https://pdf.hres.ca/dpd_pm/00065650.PDF; date not captured; DIN 02504499; fetched 2026-09-10 Product monograph ZUCLOPENTHIXOL DECANOATE · General benefit Indications CLOPIXOL (zuclopenthixol hydrochloride), CLOPIXOL ACUPHASE (zuclopenthixol acetate injection) and CLOPIXOL DEPOT (zuclopenthixol decanoate injection) are indicated for: • the management of the manifestations of schizophrenia. PM: https://pdf.hres.ca/dpd_pm/00085236.PDF; date 2026-06-30; DIN 02230406; fetched 2026-09-10 Product monograph ZUCLOPENTHIXOL DIHYDROCHLORIDE · General benefit Indications CLOPIXOL (zuclopenthixol hydrochloride), CLOPIXOL ACUPHASE (zuclopenthixol acetate injection) and CLOPIXOL DEPOT (zuclopenthixol decanoate injection) are indicated for: • the management of the manifestations of schizophrenia. PM: https://pdf.hres.ca/dpd_pm/00085236.PDF; date 2026-06-30; DIN 02230402; fetched 2026-09-10 Product monograph • the management of the manifestations of schizophrenia. CLOPIXOL (zuclopenthixol tablets as zuclopenthixol hydrochloride) may be used during initial treatment and for maintenance treatment. CLOPIXOL ACUPHASE (zuclopenthixol acetate injection) is intended for the initial treatment of acute psychotic episodes or exacerbation of psychosis associated with schizophrenia. CLOPIXOL DEPOT (zuclopenthixol decanoate injection) is intended for maintenance treatment. PM: https://pdf.hres.ca/dpd_pm/00085236.PDF; date 2026-06-30; DIN 02230402; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. INDICATIONS Schizophrenia SEROQUEL (quetiapine fumarate immediate-release) is indicated for: • the management of the manifestations of schizophrenia. The antipsychotic efficacy of SEROQUEL was established in short-term (6-week) controlled inpatient trials (see 14 CLINICAL TRIALS). The efficacy of SEROQUEL in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials of patients with manifestations of schizophrenia. Bipolar Disorder SEROQUEL is indicated as monotherapy for the: • acute management of manic episodes associated with bipolar disorder. • acute management of depressive episodes associated with bipolar I and bipolar II disorder. The efficacy of SEROQUEL in bipolar mania was established in two 12-week clinical trials of bipolar patients (see 14 CLINICAL TRIALS). The safety and effectiveness of SEROQUEL for long-term use, and for prophylactic use in bipolar mania has not been evaluated. The efficacy of SEROQUEL in bipolar depression was established in four 8-week clinical trials that included either bipolar I or bipolar II patients (see 14 CLINICAL TRIALS). 1.1 Pediatrics Pediatrics (< 18 years of age): Based on the … https://pdf.hres.ca/dpd_pm/00078929.PDF PM date: MAR 18, 2025 Source product: SEROQUEL; DIN 02236951; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.